Inpharma 1261 - 28 Oct 2000

■ Candesartan cilexetil is effective in moderate-to-severe hypertension when administered alone and incombination with amlodipine ± hydrochlorothiazide,report researchers from the UK and Israel CandesartanInvestigator Group. In this study, 216 patients withmoderate-to-severe essential hypertension receivedopen-label candesartan cilexetil (maximum dosage 16mg/day) with, if necessary, the addition of amlodipine5 mg/day and hydrochlorothiazide 25 mg/day in astepwise fashion in order to achieve BP control.*;†

Among 162 evaluable patients, overall mean seated BPwas reduced from 174/108mm Hg at baseline to141/88mm Hg. 131 patients were then randomised tocontinue candesartan cilexetil (n = 64) or to havecandesartan cilexetil replaced with placebo, foranother 4 weeks. During this phase, BP increased by asignificant extent in placebo recipients while no suchchange was seen in candesartan cilexetil recipients.* The study was supported by Takeda Euro R&D.† The dose-titration phase lasted 12 weeks.

MacGregor GA, et al. Efficacy of candesartan cilexetil alone or in combinationwith amlodipine and hydrochlorothiazide in moderate-to-severe hypertension.Hypertension 36: 454-460, Sep 2000 800846871

1

Inpharma 28 Oct 2000 No. 12611173-8324/10/1261-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved